| Literature DB >> 34201007 |
Kinan Alhallak1,2, Jennifer Sun1,2, Amanda Jeske1,2, Chaelee Park1, Jessica Yavner1, Hannah Bash1, Berit Lubben1, Ola Adebayo1, Ayah Khaskiah3, Abdel Kareem Azab1,2.
Abstract
MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.Entities:
Keywords: bispecific T cell engagers; chimeric antigen receptor-T cells; multiple myeloma
Year: 2021 PMID： 34201007 DOI： 10.3390/cancers13122853
Source DB: PubMed Journal: Cancers (Basel) ISSN： 2072-6694 Impact factor: 6.639